CN107582854B - Traditional Chinese medicine composition for treating reflux esophagitis - Google Patents
Traditional Chinese medicine composition for treating reflux esophagitis Download PDFInfo
- Publication number
- CN107582854B CN107582854B CN201710824179.6A CN201710824179A CN107582854B CN 107582854 B CN107582854 B CN 107582854B CN 201710824179 A CN201710824179 A CN 201710824179A CN 107582854 B CN107582854 B CN 107582854B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- reflux esophagitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The scheme relates to a traditional Chinese medicine composition for treating reflux esophagitis, which is prepared according to monarch, minister, assistant and guide, and angelica dahurica, eucommia bark and mistletoe are used as monarch drugs; the lysimachia christinae hance, the mangnolia officinalis, the Chinese starjasmine stem and the cortex lycii radicis are used as ministerial drugs; radix adenophorae, herba elsholtziae, centipede and oldenlandia diffusa are used as adjuvant medicines; brucea javanica, winged vine of cicada, Indian iphigenia bulb, Chinese violet and amur corktree bark are used as guiding drugs; the traditional Chinese medicine composition comprises the following components in parts by weight: 15-25 parts of angelica dahurica, 10-18 parts of eucommia ulmoides, 7-13 parts of parasitic loranthus, 3-10 parts of semen strychni, 6-12 parts of mangnolia officinalis, 4-8 parts of Chinese starjasmine stem, 3-5 parts of cortex lycii radicis, 5-10 parts of adenophora stricta, 7-15 parts of elsholtzia, 3-5 parts of centipede, 3-7 parts of oldenlandia diffusa, 1-5 parts of brucea javanica, 4-9 parts of cicada winged vine, 1-3 parts of edible tulip, 3-5 parts of spina date and 2-6 parts of cortex phellodendri. The medicine is prepared from pure traditional Chinese medicines, has no toxic or side effect, and is easy to be accepted by patients; reasonable formula, simple process and reliable curative effect.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating reflux esophagitis.
Background
Reflux Esophagitis (RE) refers to the pathological changes of inflammation, erosion, ulcer and the like of the esophageal mucosa caused by the reflux of stomach and/or duodenal contents into the esophagus, and belongs to gastroesophageal reflux disease. Patients who do not have systemic treatment for a long time or who still cannot completely control symptoms by systemic treatment can have esophageal stenosis, ulcer and upper gastrointestinal bleeding, and can seriously progress to esophageal cancer. With the improvement of the living standard of people, the dietary structure changes, the fat food increases, and the incidence of RE in China gradually increases.
According to clinical manifestations, traditional Chinese medicine belongs to the categories of acid regurgitation, chest stuffiness, chest stagnation syndrome, vomiting, noisy and globus hystericus. The pathogenic heat causes many patients. For example, Su Wen-Zhi Zhen Yao Da Lun: the adverse rising of the stomach is caused by fire, vomiting and diarrhea are caused by heat, shaoyang is predominant, heat is in the stomach, … … vomiting, acid and hunger. It is necessary to purge fire and check adverse rise of qi for vomiting sour water and vomiting due to fire and heat. However, cold and cool herbs are too old to stop qi movement and obstruct gastrointestinal peristalsis, so although the symptoms of heart burning and acid regurgitation will be relieved after the herbs are taken, some patients will also have symptoms of uncomfortable gastric cavity distention or aggravation of original distention symptoms. Clinically, it should be treated according to syndrome differentiation, although reflux esophagitis has a heat image, heartburn and acid regurgitation are not considered to be heat, as in syndrome treatment affluence and acid regurgitation: for those with sour disease, the heat of sour disease is also caused by fire when the large intestine stagnates in the middle energizer and long-term stagnated heat is transformed into heat; if cold pathogen attacks the stomach and turns into sour, there is no stagnated heat, and the cold is transformed into sour cold.
Western medicine mainly treats gastric acid secretion, improves gastric motility and the like, can only improve clinical symptoms mostly, is easy to relapse after stopping taking medicine, and has certain side effects after long-term taking medicine.
Disclosure of Invention
Aiming at the technical problems in the prior art, the traditional Chinese medicine composition for treating reflux esophagitis has a good treatment effect and no toxic or side effect on a human body.
In order to achieve the purpose, the scheme is achieved through the following technical scheme:
a Chinese medicinal composition for treating reflux esophagitis comprises principal drug, minister drug, adjuvant drug and messenger drug, wherein radix Angelicae Dahuricae, Eucommiae cortex and herba Taxilli are used as principal drug; the lysimachia christinae hance, the mangnolia officinalis, the Chinese starjasmine stem and the cortex lycii radicis are used as ministerial drugs; radix adenophorae, herba elsholtziae, centipede and oldenlandia diffusa are used as adjuvant medicines; brucea javanica, winged vine of cicada, Indian iphigenia bulb, Chinese violet and amur corktree bark are used as guiding drugs; the traditional Chinese medicine composition comprises the following components in parts by weight:
15-25 parts of angelica dahurica, 10-18 parts of eucommia ulmoides, 7-13 parts of parasitic loranthus, 3-10 parts of semen strychni, 6-12 parts of mangnolia officinalis, 4-8 parts of Chinese starjasmine stem, 3-5 parts of cortex lycii radicis, 5-10 parts of adenophora stricta, 7-15 parts of elsholtzia, 3-5 parts of centipede, 3-7 parts of oldenlandia diffusa, 1-5 parts of brucea javanica, 4-9 parts of cicada winged vine, 1-3 parts of edible tulip, 3-5 parts of spina date and 2-6 parts of cortex phellodendri.
Preferably, the traditional Chinese medicine composition for treating reflux esophagitis comprises the following specific components in parts by weight:
15 parts of angelica dahurica, 10 parts of eucommia bark, 10 parts of parasitic loranthus, 3 parts of lysimachia christinae hance, 7 parts of mangnolia officinalis, 4 parts of Chinese starjasmine stem, 3 parts of cortex lycii radicis, 5 parts of adenophora stricta, 7 parts of elsholtzia, 3 parts of centipede, 3 parts of oldenlandia diffusa, 1 part of brucea javanica, 4 parts of cicada's winged vine, 1 part of edible tulip, 4 parts of Chinese violet and 5 parts of golden cypress.
Preferably, the traditional Chinese medicine composition for treating reflux esophagitis comprises the following specific components in parts by weight:
25 parts of angelica dahurica, 18 parts of eucommia bark, 13 parts of loranthus parasiticus, 10 parts of christina loosestrife, 12 parts of mangnolia officinalis, 6 parts of Chinese starjasmine stem, 5 parts of cortex lycii radicis, 10 parts of adenophora stricta, 15 parts of elsholtzia, 5 parts of centipede, 7 parts of oldenlandia diffusa, 5 parts of brucea javanica, 9 parts of cicada's winged vine, 3 parts of edible tulip, 5 parts of Chinese violet and 6 parts of golden cypress.
An application of a Chinese medicinal composition in Chinese medicinal preparation, wherein the Chinese medicinal preparation comprises capsule, tablet, granule, powder, oral liquid and pill.
An application of a Chinese medicinal composition in treating reflux esophagitis is provided.
The invention has the beneficial effects that:
(1) reasonable formula, simple process and reliable curative effect;
(2) the medicine is prepared from pure traditional Chinese medicines, has no toxic or side effect, and is easy to be accepted by patients.
Detailed Description
The present invention is further described in detail below with reference to examples so that those skilled in the art can practice the invention with reference to the description.
Example 1
A traditional Chinese medicine composition for treating reflux esophagitis comprises the following specific components in parts by weight:
15 parts of angelica dahurica, 10 parts of eucommia bark, 10 parts of parasitic loranthus, 3 parts of lysimachia christinae hance, 7 parts of mangnolia officinalis, 4 parts of Chinese starjasmine stem, 3 parts of cortex lycii radicis, 5 parts of adenophora stricta, 7 parts of elsholtzia, 3 parts of centipede, 3 parts of oldenlandia diffusa, 1 part of brucea javanica, 4 parts of cicada's winged vine, 1 part of edible tulip, 4 parts of Chinese violet and 5 parts of golden cypress.
The preparation method comprises the following steps: putting the medicinal materials into an earthen pot, adding water with the dosage of 8 times of the medicinal materials, soaking for 2 hours, boiling the water, decocting for 3 hours by slow fire, and filtering the liquid medicine to obtain the medicine for taking.
Example 2
A traditional Chinese medicine composition for treating reflux esophagitis comprises the following specific components in parts by weight:
25 parts of angelica dahurica, 18 parts of eucommia bark, 13 parts of loranthus parasiticus, 10 parts of christina loosestrife, 12 parts of mangnolia officinalis, 6 parts of Chinese starjasmine stem, 5 parts of cortex lycii radicis, 10 parts of adenophora stricta, 15 parts of elsholtzia, 5 parts of centipede, 7 parts of oldenlandia diffusa, 5 parts of brucea javanica, 9 parts of cicada's winged vine, 3 parts of edible tulip, 5 parts of Chinese violet and 6 parts of golden cypress.
The preparation method comprises the following steps: putting the medicinal materials into an earthen pot, adding water with the dosage of 8 times of the medicinal materials, soaking for 2 hours, boiling the water, decocting for 3 hours by slow fire, and filtering the liquid medicine to obtain the medicine for taking.
Example 3
The medicine of any one of the embodiments 1-2 is taken, 6-8 times of water is added, the decoction is decocted for 2-3 hours, and the medicine juice is filtered. Adding 9 times of water, decocting for 3.5 hours, filtering out the decoction, combining the two decoctions, standing, filtering to obtain the supernatant, concentrating, cooling, adding 3.5 times of alcohol, stirring and precipitating overnight. Taking supernatant, and concentrating to obtain thick extract; adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into tablet or capsule.
Example 4
The medicine of any one of the embodiments 1-2 is taken, 8-10 times of water is added, the decoction is decocted for 3.5 hours, and the medicine juice is filtered. Adding 11 times of water, decocting for 3 hours, filtering out medicine juice, combining the two decoctions, standing, filtering to obtain supernatant, concentrating, cooling, adding 2 times of alcohol, stirring and precipitating overnight. Taking supernatant, and concentrating to obtain thick extract; adding appropriate pharmaceutical adjuvants, granulating, drying, grading to obtain 30g granule, and packaging into 10 g/bag.
Example 5 (clinical drug efficacy observation)
Age: 18-65 years old;
clinical symptoms: typical symptoms comprise heartburn, acid regurgitation, stomach diversion, discomfort due to burning pain after sternum, dysphagia, regurgitation or belching, throat discomfort and bitter taste, etc. caused by esophagitis;
inflammation was confirmed with endoscopes and living tissue;
simultaneous monitoring of pH and bilirubin in the esophagus for 24 hours confirmed the presence of reflux. The pH value is less than 4, the total time percentage is greater than 4 percent, or/and the Demeester score is greater than 14, and the bilirubin light absorption value is greater than 0.14, the total time percentage is greater than 4 percent, which is an index of the existence of acid-base mixed reflux.
Exclusion criteria:
has alarm symptoms such as emaciation, black stool, hematemesis, etc.;
hiatal hernia and peptic ulcer.
Observing the index, recording the clinical symptom integral of the patient before and 8 weeks after the administration, and checking the endoscope.
The number of the people selected: 60 people.
The treatment method comprises the following steps: the decoction according to any one of examples 1-2 is taken 2 times daily.
As a result: the clinical curative effect and the endoscope result are shown in tables 1 and 2
TABLE 1 clinical effects
| Recovery method | Show effect | Is effective | Invalidation | Total effective rate | |
| Clinical symptoms | 8 | 26 | 22 | 4 | 93 |
TABLE 2 endoscopic results
And (4) conclusion: the medicine can improve the clinical symptoms of patients with reflux esophagitis, the total clinical effective rate is 93%, the medicine can improve the reflux esophagitis, and the total endoscope effective rate is 81%.
Example 5 (animal experiment for drug effect observation)
The experimental scheme is as follows: two types of reflux esophagitis were used for modeling: acid reflux (cardia myotomy plus hemipyloric ligation) and mixed reflux (cardia myotomy plus hemiduodenal ligation) were compared with those of the sham operation group and the positive drug control group, and the therapeutic effect of any of the drugs of examples 1 to 4 on reflux esophagitis in rats was observed.
Observation indexes are as follows: and observing the number of layers of rat esophageal tissue squamous-paw epithelium, the number of papillary nodes of mucosa lamina propria and the infiltration number of submucosal neutrophils.
The experimental results are as follows:
1. action for repairing inflammation of lower esophageal mucosa of rat with acid reflux esophagitis
TABLE 3 comparison of esophageal histomorphology of rats in various groups of acid reflux esophagitis
*Compared with the model group, P is less than 0.05,#compared with the traditional Chinese medicine dosage group, P is less than 0.05.
The morphological comparison of the esophagus tissues of the rats in each group of acid reflux esophagitis is shown in table 3, and the number of the esophageal lower mucosal epithelium layer, the number of nipple nodules and the number of neutrophils in the rat model of the acid reflux esophagitis are obviously higher than those in the normal group (P is less than 0.05) according to the table 3. The traditional Chinese medicine medium-dose group is obviously superior to other groups (P is less than 0.05) in the aspect of improving the squamous epithelial thickness of the esophageal mucosa, the effect of the high-dose group is not different (P is more than 0.05) in the aspect of improving the hyperplasia of the papillary nodules of the lamina propria, and the traditional Chinese medicine low-dose group, the western medicine group and the model group (P is less than 0.05) are lower than those of the high-dose group. The effects of the traditional Chinese medicine low-dose and medium-dose groups are not different in the aspect of improving the neutrophil infiltration (P is more than 0.05), but the traditional Chinese medicine low-dose and medium-dose groups are superior to western medicine groups and model groups (P is less than 0.05). Therefore, the traditional Chinese medicine has better curative effect on repairing the oesophagus inflammation caused by acid reflux by the dosage group.
2. For mixed reflux esophagitis rat lower esophageal mucositisAction of symptomatic repair
TABLE 4 esophageal histomorphology comparison of various groups of rats with mixed reflux esophagitis
*Compared with the model group, P is less than 0.05,#compared with the traditional Chinese medicine dosage group, P is less than 0.05.
The morphological comparison of the esophagus tissues of the rats in each group of mixed reflux esophagitis rats is shown in table 4, and the number of the layers of the mucosa epithelium of the lower segment of the esophagus, the number of the nipple nodules and the number of the neutrophils in the mixed reflux esophagitis rat model are obviously higher than those in the normal group (P is less than 0.05). The curative effect of the high-dose group and the medium-dose group is not different from that of the high-dose group (P is more than 0.05) in the aspects of improving the thickness of the esophageal mucosa epithelium and the hyperplasia of the inherent layer nipple segment, but is superior to that of the traditional Chinese medicine low-dose group, the western medicine group and the model group (P is less than 0.05) and is obviously superior to that of other groups (P is less than 0.05) in the aspects of improving the neutrophil infiltration, so that the curative effect of the traditional Chinese medicine medium-dose group in repairing the esophageal inflammation caused by.
While embodiments of the invention have been disclosed above, it is not limited to the applications listed in the description and the embodiments, which are fully applicable in all kinds of fields of application of the invention, and further modifications may readily be effected by those skilled in the art, so that the invention is not limited to the specific details without departing from the general concept defined by the claims and the scope of equivalents.
Claims (5)
1. A traditional Chinese medicine composition for treating reflux esophagitis is prepared according to monarch, minister, assistant and guide, and is characterized in that: radix Angelicae Dahuricae, Eucommiae cortex, and herba Taxilli as principal drugs; the lysimachia christinae hance, the mangnolia officinalis, the Chinese starjasmine stem and the cortex lycii radicis are used as ministerial drugs; radix adenophorae, herba elsholtziae, centipede and oldenlandia diffusa are used as adjuvant medicines; brucea javanica, winged vine of cicada, Indian iphigenia bulb, Chinese violet and amur corktree bark are used as guiding drugs; the traditional Chinese medicine composition comprises the following components in parts by weight:
15-25 parts of angelica dahurica, 10-18 parts of eucommia ulmoides, 7-13 parts of parasitic loranthus, 3-10 parts of semen strychni, 6-12 parts of mangnolia officinalis, 4-8 parts of Chinese starjasmine stem, 3-5 parts of cortex lycii radicis, 5-10 parts of adenophora stricta, 7-15 parts of elsholtzia, 3-5 parts of centipede, 3-7 parts of oldenlandia diffusa, 1-5 parts of brucea javanica, 4-9 parts of cicada winged vine, 1-3 parts of edible tulip, 3-5 parts of spina date and 2-6 parts of cortex phellodendri.
2. The traditional Chinese medicine composition for treating reflux esophagitis according to claim 1, wherein the proportion of the traditional Chinese medicine composition is as follows:
15 parts of angelica dahurica, 10 parts of eucommia bark, 10 parts of parasitic loranthus, 3 parts of lysimachia christinae hance, 7 parts of mangnolia officinalis, 4 parts of Chinese starjasmine stem, 3 parts of cortex lycii radicis, 5 parts of adenophora stricta, 7 parts of elsholtzia, 3 parts of centipede, 3 parts of oldenlandia diffusa, 1 part of brucea javanica, 4 parts of cicada's winged vine, 1 part of edible tulip, 4 parts of Chinese violet and 5 parts of golden cypress.
3. The traditional Chinese medicine composition for treating reflux esophagitis according to claim 1, wherein the proportion of the traditional Chinese medicine composition is as follows:
25 parts of angelica dahurica, 18 parts of eucommia bark, 13 parts of loranthus parasiticus, 10 parts of christina loosestrife, 12 parts of mangnolia officinalis, 6 parts of Chinese starjasmine stem, 5 parts of cortex lycii radicis, 10 parts of adenophora stricta, 15 parts of elsholtzia, 5 parts of centipede, 7 parts of oldenlandia diffusa, 5 parts of brucea javanica, 9 parts of cicada's winged vine, 3 parts of edible tulip, 5 parts of Chinese violet and 6 parts of golden cypress.
4. Use of the composition of any one of claims 1-3 in the preparation of a Chinese medicinal preparation comprising capsules, tablets, granules, powders, oral liquids and pills.
5. Use of a Chinese medicinal composition according to any one of claims 1-3 in the preparation of a medicament for the treatment of reflux esophagitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710824179.6A CN107582854B (en) | 2017-09-13 | 2017-09-13 | Traditional Chinese medicine composition for treating reflux esophagitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710824179.6A CN107582854B (en) | 2017-09-13 | 2017-09-13 | Traditional Chinese medicine composition for treating reflux esophagitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107582854A CN107582854A (en) | 2018-01-16 |
| CN107582854B true CN107582854B (en) | 2020-08-18 |
Family
ID=61052065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710824179.6A Expired - Fee Related CN107582854B (en) | 2017-09-13 | 2017-09-13 | Traditional Chinese medicine composition for treating reflux esophagitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107582854B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083631A (en) * | 2012-12-11 | 2013-05-08 | 宋协勘 | Traditional Chinese medicine for treating reflux esophagitis |
| CN105148151A (en) * | 2015-09-24 | 2015-12-16 | 王栩 | Medicine for treating spleen and stomach deficiency-cold type reflux esophagitis and preparation method |
-
2017
- 2017-09-13 CN CN201710824179.6A patent/CN107582854B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083631A (en) * | 2012-12-11 | 2013-05-08 | 宋协勘 | Traditional Chinese medicine for treating reflux esophagitis |
| CN105148151A (en) * | 2015-09-24 | 2015-12-16 | 王栩 | Medicine for treating spleen and stomach deficiency-cold type reflux esophagitis and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 中医辨证治疗反流性食管炎94例临床观察;田同儒等;《河北中医》;20130828(第08期);1135-1137 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107582854A (en) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100518810C (en) | Chinese medicinal composition for treating gastroesophageal reflux disease | |
| CN103495040B (en) | Traditional Chinese medicine composition for treating reflux esophagitis and preparation method of granule formulation thereof | |
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN103071116B (en) | Traditional Chinese medicine preparation for treating esophagus cancer and preparation method thereof | |
| CN101347594B (en) | Method for preparing Chinese medicine for treating kidney-yang deficiency type diarrhea | |
| CN104524227B (en) | A kind of Chinese medicine preparation and preparation method being used for the treatment of dental caries | |
| Gong et al. | Treatment of gastric ulcer, traditional Chinese medicine may be a better choice | |
| CN103638320B (en) | A kind of Chinese medicine preparation for the treatment of acute radiation-induced esophagitis | |
| CN104548141A (en) | Digestive tract contrast agent having effect of treating gastrointestinal ulcer and good smearing effect | |
| CN104383244B (en) | It is a kind of to treat Chinese medicine composition of cancer of the esophagus and preparation method thereof | |
| CN101455772B (en) | Preparation method of traditional Chinese medicine for treating gastric heat type acute mastitis | |
| CN107582854B (en) | Traditional Chinese medicine composition for treating reflux esophagitis | |
| CN103100048B (en) | Chinese herbal preparation for treating pharyngolaryngeal cancer and preparation method thereof | |
| CN103040975B (en) | Traditional Chinese medicine composition for nursing and treating infantile diarrhea | |
| CN104258308A (en) | Traditional Chinese medicine preparation for treating cholelithiasis | |
| CN105213780B (en) | A kind of Chinese medicine composition that treating chronic gastritis and its application | |
| CN103638251A (en) | Traditional Chinese medicinal preparation for treating acute radiation-induced esophagitis | |
| CN103721156B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of digestive tract hemorrhage | |
| CN108066731B (en) | Chinese herbal medicine composition for treating Barrett esophagus and preparation method and application thereof | |
| CN107007717A (en) | A kind of pharmaceutical composition for treating stomachache syndrome of incoordination between liver and stomach | |
| CN106620084A (en) | Pharmaceutical composition for treating gastroesophageal reflux | |
| CN106110285B (en) | A kind of Chinese medicine composition and its preparation and application for being used to treat the upper respiratory tract and oesophagus tract disease | |
| CN106806680A (en) | Raw white side's prepared slices of Chinese crude drugs combination preparation, preparation method and assembly packaging | |
| KR20220001553A (en) | Composition for prevention and improvment of reflux esophagitis | |
| CN105169263A (en) | Flushing type traditional Chinese medicine for chronic cervicitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200818 Termination date: 20210913 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |